tbuckley/cabot-search huggingface dataset:
PATH-09. MGMT PROMOTER METHYLATION IS A STRONG PROGNOSTIC FACTOR FOR SURVIVAL AFTER PROGRESSION IN HIGH GRADE GLIOMAS
Authors: Yanwei Liu, Yanong Li, Xiaoguang Qiu
Journal: Neuro-Oncology (2019)

Abstract High grade gliomas (HGGs: anaplastic gliomas and GBM) are the most lethal type of primary brain tumor. Maximal resection and postoperative concurrent chemoradiotherapy, and followed with adjuvant chemotherapy is the standard treatment. But patients with HGGs have a relapse rapidly and short survival. Studies have identified many clinical characteristics and biomarkers were associated with progression free survival (PFS) and over survival (OS). However, there has not yet a comprehensive study on the effects of these factors to survival after the first progression (SAP). 319 patients with HGGs were conducted maximum resection followed by radiotherapy and/or temozolomide chemotherapy and have been confirmed the first progression. Clinical characteristics, biomarkers (IDH1/2 mutation, MGMT promoter methylation, LOH1p/19q, TP53 mutation, EGFR amplification, Ki-67 expression) and clinical interventions (extent of resection, chemoradiotherapy, operation after progression) were analyzed in accordance with SAP. The 1-year SAP was 14.2% (median SAP: 5.1 months). Significant prognostic factors of improved SAP were tumor grade, MGMT promoter methylation and Ki-67 expression in univariate analysis (p&lt; 0.05). Further multivariate analysis showed that MGMT promoter methylation and Ki-67 expression were independently prognostic markers for SAP (p&lt; 0.05). In our data, HGGs could be divided into low, intermediate and high risk groups for SAP by MGMT promoter methylation and Ki-67 expression. However, analysis of 308 patients with GBM from The Cancer Genome Atlas (TCGA) found that MGMT promoter methylation is the only prognostic marker for SAP in multivariate analysis (p&lt; 0.05). Consequently, MGMT promoter methylation is independently prognostic marker for SAP in patients with HGGs. MGMT promoter methylation, combined with Ki-67 expression, might establish a risk model for SAP and this stratification may aid in treatment strategy selection and clinical prognosis evaluation in HGGs.
Coexistence and Prognostic Significance of EVI1 Expression and Driver Mutations in KMT2A-Rearranged Acute Myeloid Leukemia
Authors: Hidemasa Matsuo, Kenichi Yoshida, Kana Nakatani, Yasuhiko Kamikubo, Daisuke Tomizawa, Takashi Taga, Nobutaka Kiyokawa, Seishi Ogawa, Manja Meggendorfer, Claudia Haferlach, Souichi Adachi
Journal: Blood (2019)
Cellular Kinetics and Anti-Therapeutic Antibody in Relapsed/Refractory B-NHL Patients Treated with JWCAR029
Authors: Zhitao Ying, Pengpeng Xu, Ming Hao, Li Wang, Shu Cheng, Wen Wu, Wen Wang, Zisong Zhou, Su Yang, Jennifer Wang, Harry Lam, James Li, Hongxia Zheng, Weili Zhao, Yuqin Song, Jun Zhu
Journal: Blood (2019)
Thrombophilia Screening in Adults Is Not Predictive of a Thrombotic Event after Bipulmonary Lung Transplantation
Authors: Patrick Van Dreden, Btissam Fatmi, Dominique Francois, Dominique Grenet, Clément Picard, Roseline Bironien, Francois Parquin, Antoine Roux, Marc Vasse
Journal: Blood (2019)
Patient-Reported Disease Burden and Age: Results from a National Patient Advocacy Survey of Patients with Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
Authors: Keith L. Dawson, Mark A. Price, Peggy Ann Torney, Victor Gonzalez, Maria Sae-Hau, Elisa S. Weiss, Brennan Mange, Carol Mansfield, Eydith J Comenencia-Ortiz, Anthony S Masaquel, Arliene Ravelo
Journal: Blood (2019)
Toward Risk-Stratified Breast Cancer Screening: Considerations for Changes in Screening Guidelines
Authors: Gretchen L. Gierach, Parichoy Pal Choudhury, Montserrat García-Closas
Journal: JAMA Oncology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Cardiovascular Disease, Aging, and Clonal Hematopoiesis
Authors: Megan A. Evans, Soichi Sano, Kenneth Walsh
Journal: Annual Review of Pathology Mechanisms of Disease (2019)

Traditional risk factors are incompletely predictive of cardiovascular disease development, a leading cause of death in the elderly. Recent epidemiological studies have shown that human aging is associated with an increased frequency of somatic mutations in the hematopoietic system, which provide a competitive advantage to a mutant cell, thus allowing for its clonal expansion, a phenomenon known as clonal hematopoiesis. Unexpectedly, these mutations have been associated with a higher incidence of cardiovascular disease, suggesting a previously unrecognized connection between somatic mutations in hematopoietic cells and cardiovascular disease. Here, we provide an up-to-date review of clonal hematopoiesis and its association with aging and cardiovascular disease. We also give a detailed report of the experimental studies that have been instrumental in understanding the relationship between clonal hematopoiesis and cardiovascular disease and have shed light on the mechanisms by which hematopoietic somatic mutations contribute to disease pathology.
The JAK1/2 Inhibitor Ruxolitinib Downregulates CXCL12 Secretion from Bone Marrow Stromal Cells and M2 Macrophage Polarization in Multiple Myeloma
Authors: Haiming Chen, Mingjie Li, Eric Sanchez, Nicole Ng, Erin Yu, Sean Bujarski, Zhengyi Yin, Tara Hekmati, Dylan Field, Jasper Wang, Isabella Nassir, Justin Huang, David Daniely, Cathy S. Wang, Ning Xu, James R. Berenson
Journal: Blood (2019)
The Splicing Modulator GEX1A Exhibits Potent Anti-Leukemic Activity Both in Vitro and In Vivo through Inducing an MCL1 Splice-Switch in Pre-Clinical Models of Acute Myeloid Leukemia
Authors: Mark Sellin, Ryan Mack, Matthew C. Rhodes, Lei Zhang, Wei Wei, Peter Breslin, Stephanie Berg, Suming Huang, Richard Taylor, Jiwang Zhang
Journal: Blood (2019)
Spatial light-modulated stimulated Raman scattering (SLM-SRS) microscopy for rapid multiplexed vibrational imaging
Authors: Kideog Bae, Wei Zheng, Zhiwei Huang
Journal: Theranostics (2019)

High speed imaging is pre-requisite for monitoring of dynamic processes in biological events. Here we report the development of a unique spatial light-modulated stimulated Raman scattering (SLM-SRS) microscopy that tailors the broadband excitation beam with sparse-sampling masks designed for rapid multiplexed vibrational imaging to monitor real-time cancer treatment effects and in vivo transport of drug solvent. Methods: We design an optimal mask pattern that enables selection of predominant windows in SRS spectrum for collective excitation at the highest possible peak power, thus providing an improved signal-to-noise ratio (SNR) without compromise of chemical specificity. The mask pattern generated is applied to the broad excitation beam using a flexible spatial light modulator. The SLM module further offers complementary function whereby rapid scanning of SRS spectrum can be facilitated prior to the mask generation, thereby making the SLM-SRS system a stand-alone imaging platform. Results: We demonstrate that SLM-SRS microscopy permits rapid multiplexed SRS imaging of polystyrene and polymethyl methacrylate beads in Brownian motion in dimethyl sulfoxide (DMSO) at 70 ms intervals without motion artiacts. We further apply SLM-SRS to monitor the therapeautic effect of mild alkaline solution on cancer cells, which shows immediate apoptotic response. Finally, we visualize in vivo penetration of DMSO into the plant tissue and evaluate acute toxicity of DMSO on cellulose and proteins within the tissue. Conclusion: We develop novel SLM-SRS microscopy and affirm its broad applicability for rapid monitoring of dynamic biological processes at the subcellular and molecular level.
Comparison of New Oral Anticoagulants (NOAC) Based Double Therapy Versus Vitamin K Antagonist Based Triple Therapy in Patients Undergoing Percutaneous Coronary Intervention with Atrial Fibrillation: A Systematic Review and Meta-Analysis
Authors: Muhammad Zain Farooq, Prasanth Lingamaneni, Muhammad Saad Farooq, Aakash Putta, Sheeba Ba Aqeel, VV Pavan Kedar Mukthinuthalapati, Ankit Mangla, Paul Rubinstein
Journal: Blood (2019)
EXTH-55. TEMOZOLOMIDE-RESISTANT GLIOMA CELLS ARE SENSITIVE TO CHLOROETHYLATING NITROSOUREA COMPOUNDS IN COMBINATION WITH ATR INHIBITORS
Authors: Christopher Jackson, Aravind Kalathil, Ranjit Bindra
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Despite decades of research, nearly all patients with glioblastoma (GBM) face recurrent disease. Temozolomide (TMZ), the drug of choice for GBM, methylates guanine bases at the O6 position (O6meG). These lesions are normally repaired by O6meG-methyltransferase (MGMT). When MGMT is deficient (e.g. in the case of promoter hypermethylation), O6meG lesions generate mispairs with thymine and activate the mismatch repair system (MMR), which is thought to be critical for the cytotoxicity of TMZ. Numerous studies have established that acquired MMR deficiency is a common mechanism of TMZ resistance that emerges in recurrent GBM. However, reversion of MGMT-methylation status is not common in recurrent GBM. Recent work from our group demonstrated that TMZ synergizes with ATR inhibitors (ATRi’s) in MGMT-methylated GBM cells. The goal of this project was to identify the specific types of alkylating agents that synergize with ATRi’s in an MGMT-methylated, MMR-deficient molecular context. RESULTS We used GBM cell lines U251 and LN229, which are both MGMT-methylated and exquisitely sensitive to TMZ in combination with ATRi at baseline, and created MMR-deficient versions through stable knockdown of MSH2. We determined that MSH2 knockdown conferred remarkable resistance in U251 and LN229 to TMZ treatment in comparison to their respective MMR-proficient counterparts. In addition, we were unable to detect synergy between ATRi’s and TMZ in the setting of MSH2 knockdown. In contrast to TMZ, we found that treatment with chloroethyl nitrosourea (CNU) alkylating agents--including lomustine--with ATRi’s was extremely effective in killing MGMT-methylated, MMR-deficient GBM cells. CONCLUSION Here, we report an exquisite synergistic interaction between ATRi’s and CNU agents in MMR-deficient, MGMT-methylated GBM cells. Future work in the lab will examine the interaction of CNU and ATRi’s with radiation therapy (RT). Because ATRi’s are known radiosensitizers, we believe that novel combinations of ATRi’s, lomustine, and re-RT may have promise in recurrent GBM.
Natural-Killer Cell Cytotoxicity Is a Diagnostic and Prognostic Marker in Adult Patients with Secondary Hemophagocytic Lymphohistiocytosis: Results from a Prospective Phase II Observational Study
Authors: Han Bi Lee, Jae-Ho Yoon, Gi June Min, Sung-Soo Park, Silvia Park, Sung-Eun Lee, Ki-Seong Eom, Yoo-Jin Kim, Seok Lee, Hee-Je Kim, Chang-Ki Min, Seok-Goo Cho, Jong Wook Lee
Journal: Blood (2019)
Co-Transplantation of Mesenchymal Stem Cells Further Improves the Prognosis of Allo-HSCT in the Treatment of High Risk and Refractory/Relapse Hematologic Malignancies: A Single-Center Retrospective Study of 175 Patients
Authors: Jinhua Ren, Xiaofeng Luo, Minmin Chen, Min Xiao, Qian Li, Kangni Lin, Zhihong Zheng, Zhizhe Chen, Jianda Hu, Ting Yang
Journal: Blood (2019)
Decreased Mortality after the First Year of Allogeneic Hematopoietic Stem Cell Transplant in Recipients of Umbilical Cord Blood Vs. Matched Related or Matched Unrelated Donors
Authors: Lauren M. Bohannon, Kristin M. Page, Yi Ren, Sin-Ho Jung, Vinay K. Giri, Meagan V. Lew, Matthew Kelly, Taewoong Choi, Cristina Gasparetto, Gwynn D. Long, Richard D. Lopez, David A. Rizzieri, Stefanie Sarantopoulos, Nelson J. Chao, Mitchell E. Horwitz, Anthony D. Sung
Journal: Blood (2019)
A Model of Platelets in the Aging Organism Reveals Increased Numbers Due to Reduced Clearance and Enhanced Activatability of Gp2b/3a and P-Selectin, Resulting in a Larger Stroke Burden
Authors: Simona Stivala, Sara Gobbato, Martin F Reiner, Thomas F Lüscher, Giovanni G Camici, Juerg H. Beer, Nicole R Bonetti
Journal: Blood (2016)
The Unaware Physician’s Role in Perpetuating Somatic Symptom Disorder
Authors: Giuliana Morabito, Egidio Barbi, Giorgio Cozzi
Journal: JAMA Pediatrics (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Absence of Islet Autoantibodies and Modestly Raised Glucose Values at Diabetes Diagnosis Should Lead to Testing for MODY: Lessons From a 5-Year Pediatric Swedish National Cohort Study
Authors: Annelie Carlsson, Maggie Shepherd, Sian Ellard, Michael Weedon, Åke Lernmark, Gun Forsander, Kevin Colclough, Qefsere Brahimi, Camilla Valtonen-Andre, Sten A. Ivarsson, Helena Elding Larsson, Ulf Samuelsson, Eva Örtqvist, Leif Groop, Johnny Ludvigsson, Claude Marcus, Andrew T. Hattersley
Journal: Diabetes Care (2019)

OBJECTIVE Identifying maturity-onset diabetes of the young (MODY) in pediatric populations close to diabetes diagnosis is difficult. Misdiagnosis and unnecessary insulin treatment are common. We aimed to identify the discriminatory clinical features at diabetes diagnosis of patients with glucokinase (GCK), hepatocyte nuclear factor-1A (HNF1A), and HNF4A MODY in the pediatric population. RESEARCH DESIGN AND METHODS Swedish patients (n = 3,933) aged 1–18 years, diagnosed with diabetes May 2005 to December 2010, were recruited from the national consecutive prospective cohort Better Diabetes Diagnosis. Clinical data, islet autoantibodies (GAD insulinoma antigen-2, zinc transporter 8, and insulin autoantibodies), HLA type, and C-peptide were collected at diagnosis. MODY was identified by sequencing GCK, HNF1A, and HNF4A, through either routine clinical or research testing. RESULTS The minimal prevalence of MODY was 1.2%. Discriminatory factors for MODY at diagnosis included four islet autoantibody negativity (100% vs. 11% not-known MODY; P = 2 × 10−44), HbA1c (7.0% vs. 10.7% [53 vs. 93 mmol/mol]; P = 1 × 10−20), plasma glucose (11.7 vs. 26.7 mmol/L; P = 3 × 10−19), parental diabetes (63% vs. 12%; P = 1 × 10−15), and diabetic ketoacidosis (0% vs. 15%; P = 0.001). Testing 303 autoantibody-negative patients identified 46 patients with MODY (detection rate 15%). Limiting testing to the 73 islet autoantibody-negative patients with HbA1c &amp;lt;7.5% (58 mmol/mol) at diagnosis identified 36 out of 46 (78%) patients with MODY (detection rate 49%). On follow-up, the 46 patients with MODY had excellent glycemic control, with an HbA1c of 6.4% (47 mmol/mol), with 42 out of 46 (91%) patients not on insulin treatment. CONCLUSIONS At diagnosis of pediatric diabetes, absence of all islet autoantibodies and modest hyperglycemia (HbA1c &amp;lt;7.5% [58 mmol/mol]) should result in testing for GCK, HNF1A, and HNF4A MODY. Testing all 12% patients negative for four islet autoantibodies is an effective strategy for not missing MODY but will result in a lower detection rate. Identifying MODY results in excellent long-term glycemic control without insulin.
Profound Alteration of Host Response in Severe Malarial Anemia By Sickle Cell Disease: Reduction of Parasite Sequestration and Inflammation, Upregulation of Angiopoietin-2
Authors: Ryan C Henrici, Casey Sautter, Robert Opoka, Ruth Namazzi, Gregory S Park, Dibyadyuti John, Andrea L Conroy, Russell E. Ware, Chandy C. John
Journal: Blood (2019)
T-Cell Clonal Expansion and Activation Associated with Durable Clinical Response to Dual BTK and CDK4/6 Inhibitor Therapy in Mantle Cell Lymphoma
Authors: Christina Y. Lee, Maurizio Di Liberto, Yang Hu, Xiangao Huang, Nancy L Bartlett, Kami J. Maddocks, John P. Leonard, Nils-Petter Rudqvist, Lorenzo Galluzzi, Peter Martin, Olivier Elemento, Selina Chen-Kiang
Journal: Blood (2019)
The mTOR Component, Rictor, Is Regulated By the Microenvironment to Control Dormancy and Proliferative States in Myeloma Cells
Authors: Syed J. Mehdi, Sarah K Johnson, Tarun K. Garg, Cody Ashby, Maurizio Zangari, Carolina D. Schinke, Sharmilan Thanendrarajan, Joshua Epstein, Brian A Walker, Frits van Rhee, Shmuel Yaccoby
Journal: Blood (2019)
High Surface Expression of CD49d (VLA-4) and CD79b Correlates with Acalabrutinib Resistance in Patients with Chronic Lymphocytic Leukemia (CLL)
Authors: Elena Bibikova, Brian Law, Tracy Clevenger, Jean Cheung, Gary De Jesus, Michael Gulrajani, Kyoko Yamaguchi, Phuong Do, Kathleen Burke, Graham Brock, Veerendra Munugalavadla, Melanie M. Frigault, John C. Byrd, Richard R. Furman, Jennifer R. Brown, Todd Covey
Journal: Blood (2019)
ATIM-09. CLINICAL TRIAL IN PROGRESS: A STUDY OF NEOADJUVANT AND ADJUVANT VB-111 FOR TREATMENT OF RECURRENT GBM
Authors: Timothy Cloughesy, Nicholas Butowski, Dror Harats, Tamar Rachmilewitz Minei, Patrick Wen
Journal: Neuro-Oncology (2019)

Abstract BACKGOUND Ofranergene obadenovec (VB-111) is a targeted anti-cancer viral based gene therapy with a dual mechanism: a broad antiangiogenic effect and induction of a tumor directed immune response. Previous study demonstrated a survival benefit for patients with recurrent glioblastoma (rGBM) treated with VB-111 monotherapy that was continued upon progression with combination treatment of VB-111 and bevacizumab. Glioblastoma is an immunologically “cold” microenvironment which fosters immunosuppression and antagonizes anti-tumor immune responses. The role of T-cell infiltration in combating cancer has been increasingly recognized and associated with improved participant outcomes. Based on these observations, this study will assess the hypothesis that neoadjuvant use of VB-111 will lead to a statistically significant increase in tumor infiltrating T lymphocyte (TIL) density within the tumor and enhanced systemic tumor-specific T cell responses. METHODS This is a multicenter, randomized, blinded, placebo-controlled, phase 2 surgical trial to evaluate early immunologic pharmacodynamic parameters for the viral cancer therapy VB-111 in rGBM. 45 participants with rGBM indicated for resection will randomized to one of three treatment arms: Neoadjuvant Arm: intravenous VB-111 prior to resection, and VB-111 every 6 weeks after resection. Adjuvant Arm: placebo prior to resection, and VB-111 every 6 weeks afterwards. The control arm will receive placebo prior to resection followed by standard of care. Upon evidence of contrast-enhancing progression, bevacizumab may be initiated as needed for supportive care and VB-111 will continue until progression is supported at two consecutive time points. Tumor samples will be obtained and archived at the time of surgery, and blood samples will be obtained as pharmacodynamic markers throughout the study to allow DNA sequencing of T cells. The primary endpoint is influence of neoadjuvant VB-111 on TIL density. Other endpoints include safety and tolerability, peripheral T cell response, tumor/microenvironment transcriptomic alteration, and PFS/OS. Study will open for enrolment in 2019.
Outcomes Following Allogeneic Stem Cell Transplantation for AML in First Completion Remission Are Comparable between MRD Negative Patients and MRD Positive Patients Receiving Induction Only and Are Superior to MRD Positive Patients Receiving Induction and Additional Therapy
Authors: Jonathan A Gutman, Prashant Sharma, Enkhtsetseg Purev, Clayton Smith, Amanda Winters, Andrew Hammes, Michael R. Loken, Daniel A Pollyea
Journal: Blood (2019)
2019 AHA/ACC Clinical Performance and Quality Measures for Adults With High Blood Pressure
Authors: Donald E. Casey, Randal J. Thomas, Vivek Bhalla, Yvonne Commodore-Mensah, Paul A. Heidenreich, Dhaval Kolte, Paul Muntner, Sidney C. Smith, John A. Spertus, John R. Windle, Gregory D. Wozniak, Boback Ziaeian
Journal: Journal of the American College of Cardiology (2019)
Ixazomib Modulates Bone Remodeling and Actives Sonic Hedgehog Pathways
Authors: Daniele Tibullo, Anna Longo, Alessandra Romano, Alessandro Barbato, Cesarina Giallongo, Michelino Di Rosa, Carmelina Daniela Anfuso, Gabriella Lupo, Concetta Conticello, Nunzio Vicario, Rosario Gulino, Rosalba Parenti, Giuseppe A. Palumbo, Giovanni Li Volti, Francesco Di Raimondo
Journal: Blood (2019)
HOUT-10. TREATMENT OUTCOME IN ADOLESCENTS AND YOUNG ADULTS (AYAS) WITH GLIOBLASTOMA
Authors: Josiah An, Adithya Chennamadhavuni, Sarah Mott, Rohan Garje
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Glioblastoma is one of the most aggressive and commonly encountered brain tumors. Standard of care includes surgical resection with adjuvant or concurrent chemoradiation which is predominantly based on adult clinical trials. Our study objective was to assess whether survival differed in AYA compared to older adults. METHODS The National Cancer Database was used to identify patients with at least surgically resected glioblastoma from 2004 to 2016. Cox regression models were utilized to estimate the effect of treatment on overall survival (OS) while accounting for immortal time bias (3-months) and clustering within facility. RESULTS Among 51,718 patients with glioblastoma identified, 2,930 patients were AYA. Multivariable analysis (MVA) shows OS was significantly higher in AYA, female, non-white, high income, unilateral cancer patients with private insurance receiving treatments in high volume facilities. OS among AYA patients was significantly lower in surgery + (radiation or chemotherapy: S+(RT or CT) group compared to surgery only (S) (HR=1.33, 95% CI 1.06–1.65), but no significant survival difference between surgery + chemoradiation (S+C+RT) groups and surgery only (HR=0.97, 95% CI 0.83–1.14). Median survival is ~28 months in AYA among S and S+C+RT groups whereas significantly lower survival (median OS ~18 months) is seen in S+RT or CT. Non-AYA patients were at 2 times increased risk of death compared to AYA patients who received the same type of treatment. CONCLUSIONS In conclusion, AYA population has more than twice the median OS in comparison to non-AYA patients. Worse overall survival was seen among S+RT or CT in comparison to S and S+RT+CT in AYA group. For patients needing either chemotherapy or radiation with surgery, possibly a trimodal approach might provide better survival advantage. Prospective studies are needed to further explore optimal treatment modalities in this unique population.